Literature DB >> 1400312

Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides.

B P Monia1, J F Johnston, D J Ecker, M A Zounes, W F Lima, S M Freier.   

Abstract

A biological reporter gene assay was employed to determine the crucial parameters for maximizing selective targeting of a Ha-ras codon 12 point mutation (G----T) using phosphorothioate antisense oligonucleotides. We have tested a series of oligonucleotides ranging in length between 5 and 25 bases, each centered around the codon 12 point mutation. Our results indicate that selective targeting of this point mutation can be achieved with phosphorothioate antisense oligonucleotides, but this selectivity is critically dependent upon oligonucleotide length and concentration. The maximum selectivity observed in antisense experiments, 5-fold for a 17-base oligonucleotide, was closely predicted by a simple thermodynamic model that relates the fraction of mutant to wild type target bound as a function of oligonucleotide concentration and affinity. These results suggest thermodynamic analysis of oligonucleotide/target interactions is useful in predicting the specificity that can be achieved by an antisense oligonucleotide targeted to a single base point mutation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400312

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Antisense cancer therapy: the state of the science.

Authors:  D M Kushner; R H Silverman
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Functional CB1 cannabinoid receptors in human vascular endothelial cells.

Authors:  J Liu; B Gao; F Mirshahi; A J Sanyal; A D Khanolkar; A Makriyannis; G Kunos
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

Review 3.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 4.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

5.  Thermodynamic basis of the enhanced specificity of structured DNA probes.

Authors:  G Bonnet; S Tyagi; A Libchaber; F R Kramer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

6.  Potent and selective gene inhibition using antisense oligodeoxynucleotides.

Authors:  W M Flanagan; R W Wagner
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

7.  Toward the therapeutic editing of mutated RNA sequences.

Authors:  T M Woolf; J M Chase; D T Stinchcomb
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

8.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity.

Authors:  L L Cummins; S R Owens; L M Risen; E A Lesnik; S M Freier; D McGee; C J Guinosso; P D Cook
Journal:  Nucleic Acids Res       Date:  1995-06-11       Impact factor: 16.971

9.  Investigation of some properties of oligodeoxynucleotides containing 4'-thio-2'-deoxynucleotides: duplex hybridization and nuclease sensitivity.

Authors:  G D Jones; E A Lesnik; S R Owens; L M Risen; R T Walker
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

10.  Triplex-forming oligonucleotides trigger conformation changes of a target hairpin sequence.

Authors:  E Brossalina; E Demchenko; Y Demchenko; V Vlassov; J J Toulmé
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.